Study: J&J and Bayer's anticoagulant Xarelto yields mixed results

04/5/2011 | Reuters

A clinical study found that Bayer and Johnson & Johnson's anticoagulant Xarelto worked as well as standard injectable drug Lovenox, by Sanofi-Aventis, in preventing blood clots after 10 days of treatment among patients hospitalized for acute illnesses. However, the incidence of bleeding among Xarelto users after 35 days of treatment was more than double the rate seen in Lovenox users.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT